Volume 143, Issue 4, Pages 917-926.e1 (October 2012) A Combination of Esomeprazole and Aspirin Reduces Tissue Concentrations of Prostaglandin E2 in Patients With Barrett's Esophagus  Gary W. Falk, Navtej S. Buttar, Nathan R. Foster, Katie L. Allen Ziegler, Catherine J. DeMars, Yvonne Romero, Norman E. Marcon, Thomas Schnell, Douglas A. Corley, Prateek Sharma, Marcia R. Cruz–Correa, Chin Hur, David E. Fleischer, Amitabh Chak, Kenneth R. DeVault, David S. Weinberg, Gary Della'Zanna, Ellen Richmond, Thomas C. Smyrk, Sumithra J. Mandrekar, Paul J. Limburg  Gastroenterology  Volume 143, Issue 4, Pages 917-926.e1 (October 2012) DOI: 10.1053/j.gastro.2012.06.044 Copyright © 2012 AGA Institute Terms and Conditions

Figure 1 CONSORT diagram showing the number of participants who were preregistered, the number of screen failures, and the number of participants who were randomized and evaluable for the primary end point. Gastroenterology 2012 143, 917-926.e1DOI: (10.1053/j.gastro.2012.06.044) Copyright © 2012 AGA Institute Terms and Conditions

Figure 2 Box plots for the absolute change in PGE2 by intervention arm. After adjusting for the interim analysis and multiple comparisons, the nominal significance level was .0247. As shown, the higher-dose aspirin + PPI intervention resulted in a significant decrease in PGE2 values as compared with aspirin placebo + PPI (P = .020), whereas the lower-dose aspirin + PPI intervention did not differ significantly from aspirin placebo + PPI (P = .096). Gastroenterology 2012 143, 917-926.e1DOI: (10.1053/j.gastro.2012.06.044) Copyright © 2012 AGA Institute Terms and Conditions

Figure 3 Box plots for the percent change in PGE2 by intervention arm. As shown, the higher-dose aspirin + PPI and lower-dose aspirin + PPI interventions resulted in significant decreases in PGE2 values as compared with aspirin placebo + PPI (P < .001). Gastroenterology 2012 143, 917-926.e1DOI: (10.1053/j.gastro.2012.06.044) Copyright © 2012 AGA Institute Terms and Conditions